Firms will validate biomarkers for endometriosis discovered using Protagen’s UNIarray platform.
Protagen and BayerHealthCare initiated a formal collaboration to clinically validate diagnostic biomarkers of endometriosis. The project builds on results of an endometriosis biomarker discovery study carried out in 2010.
It is the third project between the companies in the last three years to leverage Protagen’s UNIarray™ platform. Protagen’s initial collaboration with Bayer, signed in 2008, was focused on the discovery of biomarkers of atrial fibrillation. The firm also has ongoing collaborations with firms including MicroDiscovery, Biogen Idec, and SupreMol.
Protagen’s UNIarray technology allows the systematic identification of autoantibody signatures in blood that can represent the basis of in vitro and companion diagnostics for patient stratification and therapy selection. The platform is being exploited both in house as well as through academic and commercial partnerships to discover and validate indication-specific autoantibody signatures in autoimmune diseases, cancer, and neurodegenerative disorders. The in-house R&D programs are currently cover oncology as well as autoimmune and neurodegenerative diseases.